研究者詳細 - 増山　寿

MISC - 増山　寿

分割表示 496 件中 381 - 400 件目／全件表示 >>

P1-345 Nuclear Orphan Receptor COUP-TFIIの雌生殖器系における機能(Group 46 生殖生理・病理IX,一般演題,講演要旨,第58回日本産科婦人科学会学術講演会)

高本憲男, 井上誠司, 舛本明生, 中務日出輝, 洲脇尚子, 増山寿, 平松祐司

日本産科婦人科學會雜誌 58 ( 2 ) 485 - 485 2006年

Term delivery choriocarcinoma patient with brain and lung metastases successfully treated by etoposide, methotrexate, actomycin D, cyclophosphamide and vincristine (EMA-CO) chemotherapy

Y Hiramatsu, H Masuyama, M Ishida, K Murakami, M Sakurai

ACTA MEDICA OKAYAMA 59 ( 5 ) 235 - 238 2005年10月

記述言語：英語出版者・発行元：OKAYAMA UNIV MED SCHOOL

It is well known that antecedent term delivery and metastasis to sites other than the lungs and vagina are high risk factors for patients with gestational trophoblastic neoplasia. Here we report on a patient with choriocarcinoma who presented with brain and lung metastases after term delivery and was treated by EMA-CO chemotherapy. A 31-year-old woman delivered a healthy infant at term. Frequent episodes of hemoptysis occurred beginning 3 weeks after the delivery. On admission to our hospital, she had lesions in the uterus, lungs and brain as well as motor aphasia and hemiplagia. The pretreatment beta-hCG level was 21,000 ng/ml and the WHO score was 16 (high-risk group). The EMA-CO regimen was administrated as first-line chemotherapy and the patient achieved complete remission after 7 courses. Treatment was terminated after 11 courses and maintained with etoposide (25 mg/day) for 6 months. The patient has remained in complete remission for more than 16 years without other adjuvant therapies. We believe that EMA-CO can currently be considered the regimen of first choice for most high-risk patients with gestational trophoblastic neoplasia in view of its effectiveness and excellent tolerability.

Web of Science

researchmap

Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia

K Hirokoshi, Y Maeshima, K Kobayashi, E Matsuura, H Sugiyama, Y Yamasaki, H Masuyama, Y Hiramatsu, H Makino

AMERICAN JOURNAL OF HYPERTENSION 18 ( 9 ) 1181 - 1188 2005年9月

記述言語：英語出版者・発行元：ELSEVIER SCIENCE INC

Background: Numerous recent reports demonstrated that changes in serum levels of angiogenesis-related factors were associated with preeclampsia. Here, we determined the serum concentration of angiopoietin-2 (Ang-2), a natural antagonist of angiopoietin-1 (Ang-1) involved in promoting angiogenesis in the presence of angiogenic stimuli such as vascular endothelial growth factor (VEGF), in women with preeclampsia.
Methods: The levels of serum Ang-2 and Tie-2, a receptor for Ang-1 expressed on endothelial cells, were determined by enzyme-linked immunosorbent assay.
Results: The concentrations of serum Ang-2 were significantly elevated in healthy pregnant women (18.9 ng/ mL) as compared to nonpregnant women or women in postpartum period. Increase in the levels of serum Ang-2 was significantly suppressed in preeclamptic women (4.5 ng/mL). The serum Ang-2 concentrations inversely correlated with gestational age in healthy pregnant women, but not in preeclamptic women. The serum Ang-2 concentrations positively correlated with placental weight or mean blood pressure (BP) in healthy pregnant women,but not in preeclamptic women. The serum Ang-2 concentrations inversely correlated with proteinuria in preeclamptic women. The serum concentrations of Tie-2 were riot significantly different between preeclamptic and nonpreeclamptic women.
Conclusions: These results suggest the potential requirement of circulating Ang-2 in proper formation of placental vasculatures during pregnancy. Although we cannot exclude the possibility that suppression in the increase of serum Ang-2 levels during pregnancy in preeclampsia as a consequence rather than a cause, measurement of serum Ang-2 concentration in pregnant women may serve as a useful marker in the diagnosis and potentially in predicting subsequent development of preeclampsia.

DOI： 10.1016/j.amjhyper.2005.03.745

Web of Science

researchmap

INCREASE OF SERUM ANGIOPOIETIN-2 DURING PREGNANCY IS AMELIORATED IN WOMEN WITH PREECLAMPSIA

Kumiko Hirokoshi, Yohei Maeshima, Hitoshi Sugiyama, Yasushi Yamasaki, Hirofumi Makino, Kazuko Kobayashi, Eiji Matsuura, Hisashi Masuyama, Yuji Hiramatsu

NEPHROLOGY 10 A103 - A103 2005年6月

The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion

H Masuyama, N Suwaki, Y Tateishi, H Nakatsukasa, T Segawa, Y Hiramatsu

MOLECULAR ENDOCRINOLOGY 19 ( 5 ) 1170 - 1180 2005年5月

記述言語：英語出版者・発行元：ENDOCRINE SOC

Recent studies have revealed that pregnane X receptor (PXR) can function as a master regulator to control the expression of phase I and phase II drug-metabolizing enzymes, as well as members of the drug transporter family, including multiple drug resistance (MDR) 1, which has a major role in multidrug resistance. Previously, we have demonstrated that steroid/xenobiotics metabolism by tumor tissue through the PXR-cytochrome P-450 3A (CYP3A) pathway might play an important role in endometrial cancer. In this study, we examined which endocrine-disrupting chemicals (EDCs) and anticancer agents might be ligands for PXR and whether these chemicals enhanced PXR-mediated transcription through two different PXR-responsive elements (PXREs), CYP3A4 and MDR1, in endometrial cancer cell lines. Some steroids/EDCs strongly activated PXR-mediated transcription through the CYP3A4-responsive element compared with the MDR1-responsive element, whereas these steroids/EDCs also enhanced the CYP3A4 expression compared with the MDR1 expression. In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression. We also analyzed how these ligands regulated PXR-mediated transcription through two different PXREs. In the presence of PXR ligands, there was no difference in the DNA binding affinity of the PXR/retinoid X recptor heterodimer to each PXRE, but there were different interactions of the coactivator to each PXR/PXRE complex. These data suggested that PXR ligands enhanced PXR-mediated transcription in a ligand- and promoter-dependent fashion, which in turn differentially regulated the expression of individual PXR targets, especially CYP3A4 and MDR1.

DOI： 10.1210/me.2004-0434

Web of Science

researchmap

IV.異常分娩２．難産２）胎勢異常・回旋異常・肩甲難産.

平松祐司, 舛本明生, 高本憲男, 増山寿

産科と婦人科 72,11,1573-1579 2005年

糖尿病合併妊娠の胎盤形成におけるperoxisome proliferator activated receptor γの役割 .

洲脇尚子, 増山寿, 舛本明生, 平松祐司

糖尿病と妊娠 2005年

25歳未満の妊婦に対するGDMスクリーニングの必要性についての検討.

住田由美, 洲脇尚子, 清水恵子, 増山寿, 平松祐司, 丹羽国泰, 小国信嗣

日本産科婦人科学会中国四国合同地方部会雑誌 2005年